COT.V - Critical Outcome Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Critical Outcome Technologies Inc.

700 Collip Circle
Suite 213
London, ON N6G 4X8

Full Time Employees

Key Executives

Ms. Alison D. Silva MA, MSCEO, Pres & Director68.76kN/AN/A
Mr. Eugene Francis KellyChief Financial OfficerN/AN/AN/A
Ms. Debi Sanderson MBADirector of Resourcing & OperationsN/AN/AN/A
Dr. Richard T. Ho M.D., Ph.D.Chief Scientific OfficerN/AN/A54
Mr. Paul PapiVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. Its lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, as well as head and neck squamous cell carcinoma. The company also develops COTI-219, a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function; drug candidates for the treatment of acute myelogenous leukemia, SOX9, MRSA, multiple sclerosis, and Alzheimer’s disease; and HIV integrase inhibitors. Critical Outcome Technologies Inc. was founded in 1999 and is based in London, Canada.

Corporate Governance

Critical Outcome Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.